VRAX — Virax Biolabs Group Limited
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: GB
- Exchange: NASDAQ
- Employees: 17
- Website: https://viraxbiolabs.com
Latest SEC filings for VRAX
- 6-K — 2026-10-09
- 6-K — 2026-09-04
- EFFECT — 2026-09-04
- 424B5 — 2026-09-04
- F-3/A — 2026-09-02
- 6-K — 2026-08-26
- 6-K — 2026-08-18
- 6-K — 2026-07-31
- F-3 — 2026-07-24
- 6-K — 2026-07-16
Educational tool only — not investment advice.